Patents by Inventor Michael Balestra

Michael Balestra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20210040039
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: October 26, 2020
    Publication date: February 11, 2021
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
    Patent number: 10858342
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 8, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jennifer Burke, Zhidong Chen, Derek Cogan, John Lord, Daniel Richard Marshall, Bryan P. McKibben, Kenneth M. Meyers, Yunlong Zhang
  • NMDA antagonist prodrugs
    Patent number: 10815199
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: October 27, 2020
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASES, CARDIOVASCULAR DISEASES AND FIBROTIC DISEASES
    Publication number: 20200109131
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: June 21, 2017
    Publication date: April 9, 2020
    Inventors: Michael BALESTRA, Jennifer BURKE, Zhidong CHEN, Derek COGAN, John LORD, Daniel Richard MARSHALL, Bryan P. MCKIBBEN, Kenneth M. MEYERS, Yunlong ZHANG
  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20190152914
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: January 20, 2019
    Publication date: May 23, 2019
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA antagonist prodrugs
    Patent number: 10207994
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 19, 2019
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Aldosterone synthase inhibitors
    Patent number: 10131642
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jörg M. Bentzien, Jennifer Burke, Derek Cogan, Xin Guo, Keith R. Hornberger, John Lord, Kenneth M. Meyers, Zhaoming Xiong, Maolin Yu, Zhonghua Zhang
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20180312475
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 28, 2016
    Publication date: November 1, 2018
    Inventors: Michael BALESTRA, Jörg M. BENTZIEN, Jennifer BURKE, Derek COGAN, Xin GUO, Keith R. HORNBERGER, John LORD, Kenneth M. MEYERS, Zhaoming XIONG, Maolin YU, Zhonghua ZHANG
  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20180037550
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: October 17, 2017
    Publication date: February 8, 2018
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA antagonist prodrugs
    Patent number: 9822075
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: November 21, 2017
    Assignee: AstraZeneca AB
    Inventors: Gunnar Nordvall, Katharina Hogdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • NMDA ANTAGONIST PRODRUGS
    Publication number: 20160280647
    Abstract: Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 29, 2016
    Inventors: Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
  • Aldosterone synthase inhibitors
    Patent number: 9181272
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 10, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jennifer Burke, Zhidong Chen, Derek Cogan, Lee Fader, Xin Guo, Bryan McKibben, Daniel Richard Marshall, Peter Allen Nemoto, Hui Yu
  • Ethanamine compounds and methods of using the same
    Patent number: 9035065
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: May 19, 2015
    Assignee: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John McCauley, David Nugiel, Lihong Shen
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20140323468
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: April 28, 2014
    Publication date: October 30, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael BALESTRA, Jennifer BURKE, Zhidong CHEN, Derek COGAN, Lee FADER, Xin GUO, Bryan MCKIBBEN, Daniel Richard MARSHALL, Peter Allen NEMOTO, Hui YU
  • Ethanamine Compounds and Methods of Using the Same
    Publication number: 20120277272
    Abstract: (S)-2-methyl-1-phenyl-2-(pyridin-2-yl)propan-1-amine, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, uses of said compound or salt for therapy of depression and other conditions, and methods of treating depression and other conditions by administering said compound or salt.
    Type: Application
    Filed: March 27, 2012
    Publication date: November 1, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P. McCauley, Lihong Shen, David Nugiel
  • Ethanamine Compounds and Methods of Using the Same
    Publication number: 20120115913
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Application
    Filed: August 29, 2011
    Publication date: May 10, 2012
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P. McCauley, Lihong Shen, David Nugiel
  • Ethanamine compounds and methods of using the same 545
    Patent number: 8013165
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P McCauley, Lihong Shen, David Nugiel
  • Ethanamine Compounds and Methods of Using the Same 545
    Publication number: 20100179199
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Application
    Filed: December 22, 2009
    Publication date: July 15, 2010
    Applicant: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P. McCauley, Lihong Shen, David Nugiel
  • Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
    Publication number: 20090069340
    Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Application
    Filed: December 22, 2005
    Publication date: March 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Michael Balestra, Heather Bunting, Deborah Chen, Ian Egle, Janet Forst, Jennifer Frey, Methvin Isaac, Fupeng Ma, David Nugiel, Abdelmalik Slassi, Gary Steelman, Guang-Ri Sun, Babu Sundar, Radhakrishnan Ukkiramapandian, Rebecca Urbanek, Sally Walsh
  • Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators
    Publication number: 20090012127
    Abstract: Compounds of Formula (I) wherein E, A and R1 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 26, 2006
    Publication date: January 8, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Thomas R. Simpson, Michael Balestra, Dean G. Brown, Cathy L. Dantzman, Glen E. Ernst, William Frietze, Christopher R. Holmquist, James Kang, Frances M. McLaren, Reed W. Smith, JR., James M. Woods